| Filed On | Filing |
|---|---|
| 12 Nov 2026 | Form 4 |
| 12 Nov 2026 |
Form 3: Ondrey Aaron, Chief Financial Officer
No securities owned |
| 10 Nov 2026 | SCHEDULE 13G |
| 02 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – |
| 30 Oct 2026 |
Form 4: Podlesak Dennis, Director
Received 8,000 shares by exercise or conversion ($94.5K) · Sold 8,000 shares ($114K) |
| 29 Oct 2026 | 144 |
| 07 Aug 2026 | SCHEDULE 13G |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Total revenue of $73 million in 2Q26, a 92% year-over-year increase – |
| 14 Jul 2026 |
8-K: Other Events
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and simil... |
| 09 Jul 2026 |
Form 4: Metzger Michael A, Director
Received 32,375 shares by exercise or conversion ($207K) · Sold 32,375 shares ($785K) · Acquired 32,375 Stock Option (Right to buy) (Option Exercise/Conversion) |
| 08 Jul 2026 | 144 |
| 12 Jun 2026 |
Form 4: Botwood Nicholas A.j., Head of R&D, CMO
Received 22,515 shares by exercise or conversion ($311K) · Sold 34,280 shares ($617K) · Acquired 22,515 Stock options (Right to buy) (Option Exercise/Conversion) · 3 more |
| 12 Jun 2026 | 144 |
| 11 Jun 2026 | 144 |
| 10 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
INDENTURE dated as of June 10, 2026 between SYNDAX PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking as... |
| 10 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Adoption Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will become av... |
| 04 Jun 2026 | DEFA14A |
| 04 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
Syndax Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), is offering a new series of its Convertible Senior Notes due 2031 (the “Notes”). The Notes will be convertible into cash, shares (“Underlying Shares”) of common stock... |
Loading...